SCHEMBL29783676

SCHEMBL29783676

CC(C)(C)OC(=O)Nc1cccc2ccn(S(=O)(=O)c3ccccc3)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 5/20 0.45
▸ PPARD Q03181 5/20 0.45
▸ PPARA Q07869 4/20 0.45
▸ HTR6 P50406 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CYP2C19 P33261 1/20 0.41
▸ ACLY P53396 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ BRD9 Q9H8M2 1/20 0.39
▸ KAT6A Q92794 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22111128 1.00 PPARG (0.45) PPARGPPARDPPARAHTR6MEN1
SCHEMBL25032374 0.84 HTR6 (0.39) PPARGPPARDPPARAHTR6MEN1
SCHEMBL31270507 0.84 HTR6 (0.39) PPARGPPARDPPARAHTR6MEN1
SCHEMBL20742914 0.83 HTR6 (0.51) PPARGPPARDPPARAHTR6MEN1
SCHEMBL20742940 0.82 HTR6 (0.53) PPARGPPARDPPARAHTR6MEN1
SCHEMBL29783668 0.82 HTR6 (0.53) PPARGPPARDPPARAHTR6MEN1
SCHEMBL20762446 0.76 MEN1 (0.54) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL29783654 0.76 MEN1 (0.54) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL22074264 0.76 HTR6 (0.54) PPARGPPARDPPARAHTR6MEN1
SCHEMBL29783655 0.76 HTR6 (0.54) PPARGPPARDPPARAHTR6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668867-B1 SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS UNIV REGENSBURG (DE) 2023-10-04 — — EP disclosed
US-11384076-B2 Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors UNIVERSITÄT REGENSBURG (DE) 2022-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384076-B2 Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors FLT3, CSF3R, ABL1 PPARG 2699/4885PPARD 2733/4885PPARA 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback